NCT04840823View on ClinicalTrials.gov

Enoxacin for Amyotrophic Lateral Sclerosis (ALS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2023

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Enoxacin

Oral 200mg tablet

DRUG

Placebo

Oral tablet

Trial Locations (1)

H3A 2B4

Montreal Neurological Institute-Hospital, Montreal

Sponsors

Collaborators (1)

Apotex Inc.
All Listed Sponsors
collaborator

Weizmann Institute of Science

OTHER

collaborator

Apotex Inc.

INDUSTRY

lead

McGill University

OTHER